The
Latest

back to news >

Our bench strength is in our extensive experience and team approach. We strive to facilitate each of our client’s needs through strategy, research, and collaboration.

September 11, 2024

Related Posts

IND to FDA Approval: Acute Agitation in Schizophrenia and Bipolar Disorders
IND to FDA Approval: Acute Agitation in Schizophrenia and Bipolar Disorders
Gallery

IND to FDA Approval: Acute Agitation in Schizophrenia and Bipolar Disorders

September 17, 2024
Phase I Studies: On Time with Quality Data
Phase I Studies: On Time with Quality Data
Gallery

Phase I Studies: On Time with Quality Data

July 26, 2024
Tight Timelines: The Biotech Existence
Tight Timelines: The Biotech Existence
Gallery

Tight Timelines: The Biotech Existence

June 20, 2024

FDA Approval: Novel Formulation for Treatment of Schizophrenia

Driving FDA Approvals with Precision and Speed

Discover how CRC’s expertise in clinical trial management supported the FDA approval of a novel formulation for schizophrenia treatment. Download the full case study to explore the challenges faced, proactive solutions implemented, and the strategic approach that delivered results on time and on budget.